Clinical Trials
50 trialsA Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
Janssen Research & Development, LLC
KLK2-PASenger
Janssen Research & Development, LLC
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Amgen
InavoPC
Hoffmann-La Roche
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
National Cancer Institute (NCI)
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Alliance for Clinical Trials in Oncology
IDeate-Prostate02
Merck Sharp & Dohme LLC
MK-2400-001
Merck Sharp & Dohme LLC
TroFuse-031
Merck Sharp & Dohme LLC
A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer
National Institutes of Health Clinical Center (CC)
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
Telix Pharmaceuticals (Innovations) Pty Limited
MK-5684-01A
Merck Sharp & Dohme LLC
ABLE-22
Ferring Pharmaceuticals
HAYATE
Bayer
A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)
Memorial Sloan Kettering Cancer Center
rechARge
Celgene
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
BioNTech SE
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)
Sichuan Baili Pharmaceutical Co., Ltd.
Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC
University of Iowa
OPTION-DDR
Canadian Cancer Trials Group
ADAPT-BLADDER
Hoosier Cancer Research Network
Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients
Charles Drew University of Medicine and Science
TRIPLE-SWITCH
Canadian Cancer Trials Group
In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial
Mayo Clinic
THUNDER
Cancer Research Antwerp
Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer
University of Florida
Intravesical Gem/Doce in Patients With NMIBC
University of Arizona
KEYNOTE-365
Merck Sharp & Dohme LLC
Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors
Oscotec Inc.
A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients
Shanghai Jiao Tong University School of Medicine
A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
STAMPEDE2
University College, London
Study on Triple Therapy Combined With HIFU for High-Tumor-Burden mHSPC
Qilu Hospital of Shandong University
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
SWOG Cancer Research Network
HS-10502
Jiangsu Hansoh Pharmaceutical Co., Ltd.
HGNMIBC
Relmada Therapeutics, Inc.
PKUFH-GS5
Peking University First Hospital
Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer
Rigshospitalet, Denmark
ProBio
Karolinska Institutet
PSA-DEEP02
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
GAIN INST
Hospital Centre Biel/Bienne
Lead4Care
Uppsala University
Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer
Zhuhai Beihai Biotech Co., Ltd
Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)
UNICANCER
GUNS
University of British Columbia
DAROTAXEL
Erasmus Medical Center
ECHOS
Santa Chiara Hospital
SEGNO
The First Affiliated Hospital of Xiamen University
Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC
The First Affiliated Hospital with Nanjing Medical University